
BUTAJECT - phenylbutazone injection Butler Animal Health Supply

BUTAJECT (Phenylbutazone Injection) 200 mg/mL

For Horses Only

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION: Phenylbutazone 20% Injection (phenylbutazone) is a synthetic, nonhormonal anti-inflammatory, antipyretic compound useful in the management of inflammatory conditions. The apparent analgesic effect is probably related mainly to the compound's anti-inflammatory properties. Chemically, phenylbutazone is 4-butyl-1,2-diphenyl-3,5-pyrazolidinedione. It is a pyrazolon derivative entirely unrelated to the steroid hormones, and has the following structural formula:



BACKGROUND PHARMACOLOGY

Kuzell, ^{1, 2, 3} Payne, ⁴ Fleming, ⁵ and Denko ⁶ demonstrated clinical effectiveness of phenylbutazone in acute rheumatism, gout, gouty arthritis and various other rheumatoid disorders in man. Anti-rheumatic and anti-inflammatory activity has been well established by Fabre, ⁷ Domenjoz, ⁸ Wilhelmi, ⁹ and Yourish. ¹⁰ Lieberman ¹¹ reported on the effective use of phenylbutazone in the treatment of painful conditions of the musculosketal system in dogs; including posterior paralysis associated with intervertebral disc syndrome, painful fractures, arthritis, and painful injuries to the limbs and joints. Joshua ¹² observed objective improvement without toxicity following long-term therapy of two aged arthritic dogs. Ogilvie and Sutter ¹³ reported rapid response to phenylbutazone therapy in a review of 19 clinical cases including posterior paralysis, posterior weakness, arthritis, rheumatism, and other conditions associated with lameness and musculoskeletal weakness.

Camberos¹⁴ reported favorable results with phenylbutazone following intermittent treatment of Thoroughbred horses for arthritis and chronic arthrosis (e.g., osteoarthritis of medial and distal bones of the hock, arthritis of stifle and hip, arthrosis of the spine, chronic hip pains, achronic pain in the trapezius muscles, and generalized arthritis). Results were less favorable in cases of traumatism, muscle rupture, strains and inflammations of the third phalanx. Sutter¹⁵ reported favorable response in chronic equine arthritis, fair results in a severely bruised mare, and poor results in two cases where the condition was limited to the third phalanx

INDICATIONS

For relief of inflammatory conditions associated with the musculoskeletal system in horses.

CONTRAINDICATIONS

Treated animals should not be slaughtered for food purposes. Parenteral injections should be made intravenously only; do not inject subcutaneously or intramuscularly. Use with caution in patients who have a history of drug allergy.

PRECAUTIONS

Stop medication at the first sign of gastrointestinal upset, jaundice, or blood dyscrasia. Authenticated cases of agranulocytosis associated with the drug have occurred in man. To guard against this possibility, conduct routine blood counts at weekly intervals of two weeks thereafter. Any significant fall in th total white count, relative decrease in granulocytes, or black or tarry stools, should be regarded as a signal for immediate cessation of therapy and institution of appropriate counter measures. In the treatment of inflammatory conditions associated with infections, specific anti-infective therapy is required.

Store in refrigerator between 2° - 8°C (36° - 46°F)

DOSAGE AND ADMINISTRATION

HORSES

INTRAVENOUSLY: 1 to 2 g per 1,000 lbs of body weight (5 to 10 mL/1,000 lbs) daily. Injection should be given slowly and with care. Limit intravenous administration to a maximum of 5 successive days, which may be followed by oral phenylbutazone dosage forms.

GUIDELINES TO SUCCESSFUL THERAPY

- 1. Use a relatively high dose for the first 48 hours, then reduce gradually to a maintenance dose. Maintain lowest dose capable of producing desired clinical response.
- 2. Response to phenylbutazone therapy is prompt, usually occurring within 24 hours. If no significant clinical response is evident after 5 days, reevaluate diagnosis and therapeutic approach.
- 3. In animals, phenylbutazone is largely metabolized in 8 hours. It is recommended that a third of the daily dose be administered at 8 hour intervals. Reduce dosage as symptoms regress. In some cases, treatment may be given only when symptoms appear with no need for continuous medication. If long-term therapy is planned, oral administration is suggested.
- 4. Many chronic conditions will respond to phenylbutazone therapy, but discontinuance of treatment may result in recurrence of symptoms.

HOW SUPPLIED

INJECTABLE: For Horses only: 100 mL vials, 200 mg/mL (1 g/5 mL) Each mL contians 200 mg of phenylbutazone, 10.45 mg of benzyl alcohol as preservative, sodium hydroxide to adjust pH to 9.5 to 10.0, and water for injection, Q.S.

REFERENCES

- 1. Kuzell, W.C., Schaffarzick, R.W., Naugler, W.G., and Mankle, E.A.: AMA Arch. Int. Med. 92:646, 1953.
- 2. Kuzell, W.C., Schaffarzick, R.W., Brown, B. and Mankle, E.A.: Jour. Amer. Med. Assoc. 149:729, 1952.
- 3. Kuzell, W.C., Schaffarzick, R.W., Calif. Med. 777:319, 1952.
- 4. Payne, R.W., Shetlar, M.R., Farr, C., Hellbaum, A.A., and Ishmael, W.K.T.: J.Lab. Clin. Med. 45:331, 1955.
- 5. Fleming, J. and @Will, G.: Ann Rheumat. Dis. 12:95, 1953.
- 6. Denko, C.W., and Rumi, D.: Amer. Practit. 6:1865, 1955.
- 7. Fabre, J. and Berger, A.: Semaine Hop. (Paris) 31:87, 1955.
- 8. Domenjoz, R., Theobald, W. and Morsdorf, K., Arzneimittel-Forsch. 5:488, 1955.
- 9 Wilhelmi, G., and Pulver, R.: Arzneimittel-Forsch. 5:221, 1955.
- 10. Yoursh, N., Paton, B., Brodie, B.B and Burns, J.J.: AMA Arch. Ophth. 53:264, 1955.
- 11. Lieberman, L.L.: Jour. Amer. Vet. Med. Assoc. 125:128, 1954.

- 12. Joshua, J.O.: Vet. Rec. 68:60 (Jan 21), 1956.
- 13. Ogilvie, F.B. and Sutter, M.D.: Vet. Med 52:492-494, 1957.
- 14. Camberos, H.R.: Rev. Med. Vet. (Buenos Aires); 38:9, 1956.
- 15. Sutter, M.F.: Vet Med. 53:83 (Feb.), 1958.

INDICATIONS

For relief of inflammatory conditions associated with the musculoskeletal system in horses.

Intravenous dos age (not subcutaneous or intramus cular use):

Horses: 1 to 2 g per 1,000 lb body weight (5 to 10 mL/1,000 lb) daily.

Not for use in Horses intended for food.

See package outsert for additional information.

Each mL contains:

Store in a refrigerator between 2°C and 8°C (36°F and 46°F).


TAKE TIME OBSERVE LABEL DIRECTIONS

FOR HORSES ONLY

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

KEEP OUT OF REACH OF CHILDREN

ANADA 200-371, Approved by FDA



- Kuzell, W.C., Schaffarzick, R.W., Naugler, W.G., and Mankle, E.A.: AMA Arch. Int. Med. 92:646, 1953.
- E.A.: MAA Arch. Inf. Mod. 32548, 1953.

 S. Kuzell, W.C., Schriffstrock, R.W., Brown, B. and Manike, E.A.: Jour. Arner. Med. Assoc. 149 729, 1952.

 3. Kuzel, W.C., Schriffstrock, R.W., Calff, Med. 77:319, 1952.

 4. Payve, R.W., Shetlar, M.R. Farr, C., Helbeum, A.A. and Ishmad, W.K.T.: J. Lab. Clin. Med. 45:331, 1956.
- Shmale, W.K.I.: J. Lab. Cin. Med. 45331, 1950.
 5 Feming, J. and Will. G.: Ann Rhemart. Dis. 1255, 1953.
 6 Denko, C.W., and Rurri, D.: Amer. Practt. 6:1865, 1955.
 7. Fafre, J. and Berger, A.: Semaine Hop. (Penis) 31:87, 1965.
 8 Domenipe, R. Theobeld, W. and Morsdorf, K.; Azzminifite-Forsch, 5:488, 1955.
- Pulsan, Joseph Storm, R.; Arzneimittel-Forsch, 5,221, 1955. 10. Yourish, N., Patron, B., Brodie, B.B. and Burns, J.J.; AMA Arch, Ophih. 53,264, 1955. 11. Lieberman, L.L.; Jour, Amer, Vet, Med. Assoc. 125,128, 1954.
- Joshua, J.O.: Vet. Rec. 68:60 (Jan. 21), 1956.
 Ogilvie, F.B. and Sutter, M.D.: Vet. Med. 52:492-494, 1957.
- s, H.R.: Rev. Med. Vet. (Buenos Aires); 38.9, 1956. 15. Sutter, M.D.: Vet. Med. 53:83 (Feb.), 1958.

Each mL contains:

. 200 mg Phenylbutazone . Benzyl Alcohol (as preservative) 10.45 mg Sodium hydroxide to adjust pH to 9.5 to 10.0 Water For Injection q.s.

Store in a refrigerator between 2°C and 8°C (36°F and 46°F).



Reorder #: 002476

Manufactured by Lenexa, KS 66215

P-4825-04 Rev. 07-10



BUTAJECT

For Horses Only CAUTION: Federal law restricts this drug to use by or on

CAUTION: Federal law restricts this drug to use by or on the order of a locensed eveterinary. DESCRIPTION: BUTALECT (Phenylbuszone Injection) is a synthetic, nonhommeral arti-inflammatory, antipyretic compound useful in the management of inflammatory conditions. The apperent analgesie effect is probably related mainly to the compounds sarti-inflammatory properties. Chemically, phenylbutzone is 44byl-14.2-diphenyl-3-5-pyre-zidifinactione. It is a pyrazotion derivative entirely urrelated to the steroid hommones, and has the following structural formula:

BACKGROUND PHARMACOLOGY: Kuzell. 1.2.3 Payne, Fleming, and Denko demonstrated clinical effectiveness of phenylbutazone in acute rheumatism, gout, gouty arthritis, and various other rheumatoid disorders in man. Anti-rheumatic and anti-inflammatory activity has been well established by Fabre. Domenjoz, ⁸ Wilhelmi, ⁹ and Yourish. ¹⁰ Lieberman¹¹ reported on the effective use of phenylbutazone in the treatment of painful conditions of the musculoskeletal system in dogs; including posterior paralysis associated with intervertebral disc syndrome, painful fractures, arthritis, and painful injuries to the limbs and joints. Joshua 12 observed objective improvement without toxicity following long-term therapy of two aged arthritic dogs. Ogilivle and Sutter¹³ reported rapid response to phenylbutazone therapy in a review of 19 clinical cases including posterior paralysis, posterior weakness, arthritis, rheumatism, and other conditions associated with lameness and musculo-skeletal weakness.

Camberos¹⁴ reported favorable results with phenylbu-Camberos "reported favorable results with phenylbu-tazone following intermittent treatment of Thoroughbred horses for arthritis and chronic arthrosis (e.g., osteoarthritis of medial and distal bones of the hook, arthritis of stifle and hip, arthrosis of the spine, chronic hip pains, chronic pain in trapezius muscles, and generalized arthritis). Results were less favorable in cases of traumatism, muscle rupture, strains and inflammations of the third phalans. Sutter? reported favorable response in chronic equine arthritis, far results in a severely hustled mare and proc results in two passes in a severely bruised mare, and poor results in two cases where the condition was limited to the third phalanx.

INDICATIONS: For relief of inflammatory conditions associated with the musculoskeletal system in horses.

CONTRAINDICATIONS: Treated animals should not be slaughtered for food purposes. Parenteral injections should be made intravenously only; do not inject subcutaneously or intramusoularly. Use with caution in patients who have a history of drug allergy.

PRECAUTIONS: Stop medication at the first sign of gastrointestinal upset, jaundice, or blood dyscrasia. Authenticated cases of agranulocytosis associated with the drug have occurred in man. To guard against this possibility, conduct routine blood counts at weekly intervals during the early phase of therapy and at intervals of two weeks thereafter. Any significant fall in the total white count, relative decrease in granulocytes. or black or tarry shoots, should be regarded as a signal for immediate cessation of therapy and institution of appropriate counter measures. In the treatment of inflammatory conditions associated with infections, specific anti-infective therapy is required.

Store in a refrigerator between 2°C - 8°C (36°F - 46°F).

DOSAGE AND ADMINISTRATIONS

HORSES INTRAVENOUSLY: 1 to 2 g per 1,000 lbs of body weight (5 to 10 mL/1,000 lbs) daily, Injection should be given slowly and with care. Limit intravenous administration to a maximum of 5 successive days, which may be followed by oral phenylbutazone dosage forms.

- GUIDELINES TO SUCCESSFUL THERAPY

 1. Use a relatively high dose for the first 48 hours, then reduce gradually to a maintenance dose. Maintain lowest dose capable of producing desired desired response. clinical response
- clinical response.

 2. Response to phenylbutazone therapy is prompt, usually occurring within 24 hours. If no significant clinical response is evident after 5 days, reevaluate diagnosis and therapeutic approach.

 3. In animals, prienylbutazone is largely metabolized in 8 hours. It is recommended that a third of the daily dose be administered at 8 hour intervals. Reduce doseg as accordance press. In some assect treatment ray be
- symptoms regress. In some cases, treatment may be

given only when symptoms appear with no need for continuous medication. If long-term therapy is planned, oral administration is suggested.

4. Many chronic conditions will respond to phenylbutazone therapy, but discontinuance of treatment may result in recurrence of symptoms.

HOW SUPPLIED

INJECTABLE: For Horses only: 100 mL vials, 200 mg/mL (1 g/5 mL) Each mL contains 200 mg of shenylbutazone, 10.45 mg of benzyl alcohol as preservative, sodium hydroxide to adjust pH to 9.5 to 10.0, and water for

BUTAJECT

phenylbutazone injection

Product Information PRESCRIPTION ANIMAL DRUG NDC:11695-Product Type Item Code (Source) LABEL 4144 INTRAVENOUS Route of Administration **DEA Schedule**

Active Ingredient/Active Moiety Ingredient Name **Basis of Strength** Strength PHENYLBUTAZONE (PHENYLBUTAZONE) **PHENYLBUTAZONE** 200 mg in 1 mL

Packaging					
# Item Code	Package Description	Marketing Start Date	Marketing End Date		
1 NDC:11695-4144-1	100 mL in 1 VIAL				

Marketing Information					
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date		
ANADA	ANADA200371	02/18/2009			

Labeler - Butler Animal Health Supply (017880659)

Revised: 1/2013 Butler Animal Health Supply